Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of cell-derived monovalent H1N1 swine-origin influenza vaccine formulations in healthy adults
2009-013639-39Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of cell-derived monovalent A/H1N1 swine-origin influenza vaccine in influenza pandemic (2 arms), sponsored by Novartis. Primary endpoints: Primary immunogenicity success criteria by hemagglutination inhibition and Safety and tolerability. Started Jul 2009; status: completed.
02
Drugs
cell-derived monovalent A/H1N1 swine-origin influenza vaccine
03
Conditions
influenza pandemic
Beyond the preview
Go deeper on 2009-013639-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013639-39.